BR112017018413A2 - tratamento de pancreatite - Google Patents
tratamento de pancreatiteInfo
- Publication number
- BR112017018413A2 BR112017018413A2 BR112017018413-3A BR112017018413A BR112017018413A2 BR 112017018413 A2 BR112017018413 A2 BR 112017018413A2 BR 112017018413 A BR112017018413 A BR 112017018413A BR 112017018413 A2 BR112017018413 A2 BR 112017018413A2
- Authority
- BR
- Brazil
- Prior art keywords
- pancreatitis treatment
- pancreatitis
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562126386P | 2015-02-27 | 2015-02-27 | |
US62/126,386 | 2015-02-27 | ||
PCT/US2016/019924 WO2016138472A1 (en) | 2015-02-27 | 2016-02-26 | Pancreatitis treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112017018413A2 true BR112017018413A2 (pt) | 2018-07-24 |
BR112017018413B1 BR112017018413B1 (pt) | 2023-05-02 |
Family
ID=56789809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017018413-3A BR112017018413B1 (pt) | 2015-02-27 | 2016-02-26 | Uso de inibidores intracelulares de sinalização de cálcio no tratamento de pancreatite, composições e compostos relacionados |
Country Status (19)
Country | Link |
---|---|
US (5) | US11311535B2 (pt) |
EP (3) | EP3778595B1 (pt) |
JP (3) | JP6985146B2 (pt) |
KR (1) | KR20180006880A (pt) |
CN (3) | CN107530333B (pt) |
AR (1) | AR103807A1 (pt) |
AU (1) | AU2016224993B2 (pt) |
BR (1) | BR112017018413B1 (pt) |
CA (1) | CA2978007A1 (pt) |
DK (1) | DK3778595T3 (pt) |
EA (2) | EA036265B1 (pt) |
ES (2) | ES2899197T3 (pt) |
HK (1) | HK1244686A1 (pt) |
HU (1) | HUE056287T2 (pt) |
IL (1) | IL254116B2 (pt) |
PL (1) | PL3778595T3 (pt) |
PT (1) | PT3778595T (pt) |
TW (1) | TWI771269B (pt) |
WO (1) | WO2016138472A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
PE20170129A1 (es) | 2014-06-03 | 2017-03-30 | Actelion Pharmaceuticals Ltd | Compuestos de pirazol y su uso como bloqueadores de los canales de calcio tipo t |
DK3778595T3 (da) | 2015-02-27 | 2021-10-18 | Calcimedica Inc | Pancreatitisbehandling |
EP3331525B1 (en) | 2015-08-07 | 2020-10-07 | Calcimedica, Inc. | Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury |
JP2020506179A (ja) * | 2017-01-26 | 2020-02-27 | カルシメディカ,インク. | Cracチャネル阻害剤組成物 |
US10961242B2 (en) | 2017-05-17 | 2021-03-30 | Legochem Biosciences, Inc. | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same |
KR101798840B1 (ko) * | 2017-05-17 | 2017-11-17 | 주식회사 레고켐 바이오사이언스 | 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물 |
CN110063945B (zh) * | 2019-04-15 | 2021-07-09 | 温州医科大学 | 一种用于急性胰腺炎治疗的胆红素纳米颗粒及其制备方法 |
WO2020227312A1 (en) * | 2019-05-06 | 2020-11-12 | Calcimedica, Inc. | Synthesis of crac channel inhibitors |
CN114206850B (zh) * | 2019-09-25 | 2024-01-26 | 辰欣药业股份有限公司 | 作为crac抑制剂的2h-苯并吡喃衍生物 |
CA3172249A1 (en) * | 2020-03-20 | 2021-09-23 | Calcimedica, Inc. | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome |
EP4153179A1 (en) * | 2020-05-20 | 2023-03-29 | Calcimedica, Inc. | Methods and compositions for treating acute kidney injury |
JP2023539436A (ja) * | 2020-08-07 | 2023-09-14 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 膵臓癌の評価および処置のための方法および組成物 |
WO2022179577A1 (zh) * | 2021-02-25 | 2022-09-01 | 南京明德新药研发有限公司 | 一种环丙基取代的苯并呋喃类化合物的晶型及其制备方法 |
CN113424795B (zh) * | 2021-05-24 | 2022-09-09 | 四川大学华西医院 | 一种急性胰腺炎动物模型的构建方法和用途 |
CN113903460A (zh) * | 2021-12-10 | 2022-01-07 | 中国医学科学院北京协和医院 | 一种预测重症急性胰腺炎的系统及其应用 |
WO2023141523A1 (en) * | 2022-01-20 | 2023-07-27 | Calcimedica, Inc. | Methods and compositions for treating inflammation injury in the lungs |
CN114522157B (zh) * | 2022-02-23 | 2023-08-15 | 重庆大学 | 钙离子螯合剂在制备用于提高血管内皮细胞吞噬能力的制剂中的应用 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5424289A (en) | 1977-07-26 | 1979-02-23 | Mitsubishi Chem Ind Ltd | Production of spherical diatomaceous earth carrier |
US6093723A (en) | 1996-08-09 | 2000-07-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | 4-substituted beta-carbolines and analogs thereof |
AU751139B2 (en) | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
AU3387999A (en) | 1998-04-08 | 1999-10-25 | Abbott Laboratories | Pyrazole inhibitors of cytokine production |
CA2332957A1 (en) | 1998-06-05 | 1999-12-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
US20010044445A1 (en) | 1999-04-08 | 2001-11-22 | Bamaung Nwe Y. | Azole inhibitors of cytokine production |
WO2001014339A2 (en) | 1999-08-20 | 2001-03-01 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
JP3910319B2 (ja) | 1999-09-13 | 2007-04-25 | 株式会社小糸製作所 | 自動車用灯具 |
EP1143013A1 (en) | 2000-04-03 | 2001-10-10 | Warner-Lambert Company | Methods and compositions for screening Icrac modulators |
WO2002096416A1 (en) | 2001-05-31 | 2002-12-05 | Cellegy Pharmaceuticals, Inc. | Store operated calcium influx inhibitors and methods of use |
GB0225554D0 (en) | 2002-11-01 | 2002-12-11 | Syngenta Participations Ag | Chemical compounds |
JP4896518B2 (ja) | 2002-12-13 | 2012-03-14 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | ニコチンアミド系キナーゼ阻害薬 |
EP1575918A2 (en) | 2002-12-19 | 2005-09-21 | Neurogen Corporation | Substituted biaryl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators |
US7645588B2 (en) | 2003-03-04 | 2010-01-12 | Calcimedica, Inc. | Composition comprising a cell comprising a STIM1 protein and an agent that modulates intracellular calcium and methods of use |
KR20060058092A (ko) | 2003-07-23 | 2006-05-29 | 신타 파마슈티칼스 코프. | 염증 및 면역에 이용되는 화합물 |
DE102004005785A1 (de) | 2004-02-06 | 2005-08-25 | Bayer Cropscience Ag | 2-Halogenfuryl/thienyl-3-carboxamide |
WO2006006569A1 (ja) | 2004-07-12 | 2006-01-19 | Nihon Nohyaku Co., Ltd. | フェニルピリジン類又はその塩類、これらを有効成分とする除草剤及びその使用方法 |
CN101083985A (zh) | 2004-09-21 | 2007-12-05 | 幸讬制药公司 | 用于炎症及免疫相关用途的化合物 |
US8557861B2 (en) | 2004-09-28 | 2013-10-15 | Mast Therapeutics, Inc. | Low oil emulsion compositions for delivering taxoids and other insoluble drugs |
TWI441819B (zh) | 2005-01-07 | 2014-06-21 | Synta Pharmaceuticals Corp | 用於炎症及免疫相關用途之化合物 |
TWI422376B (zh) | 2005-01-25 | 2014-01-11 | Synta Pharmaceuticals Corp | 用於炎症及免疫相關用途之化合物 |
EP1846388A4 (en) | 2005-01-25 | 2011-12-07 | Synta Pharmaceuticals Corp | THIOPHEN COMPOUNDS FOR IGNITIONS AND THE IMMUNE SYSTEM APPLICATIONS |
JP5123671B2 (ja) | 2005-02-17 | 2013-01-23 | シンタ ファーマシューティカルズ コーポレーション | 増殖性疾患の治療のための化合物 |
EP1879881A2 (en) | 2005-04-14 | 2008-01-23 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
EP1937270A1 (en) | 2005-09-21 | 2008-07-02 | Brystol-Myers Squibb Company | Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof |
NL2000284C2 (nl) | 2005-11-04 | 2007-09-28 | Pfizer Ltd | Pyrazine-derivaten. |
HUE032640T2 (en) | 2005-11-08 | 2017-10-30 | Vertex Pharma | Heterocyclic modulator of ATP-binding cassette transcripts |
CA2628630A1 (en) | 2005-11-15 | 2007-05-24 | Baxter International Inc. | Compositions of lipoxygenase inhibitors |
EP1984400B1 (en) | 2006-01-05 | 2012-11-28 | Immune Disease Institute, Inc. | Regulators of nfat |
CA2640090A1 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Substituted aromatic compounds for inflammation and immune-related uses |
WO2007087429A2 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Phenyl and pyridyl compounds for inflammation and immune-related uses |
EP1998612A4 (en) | 2006-01-25 | 2010-11-24 | Synta Pharmaceuticals Corp | SUBSTITUTED BIARYL COMPOUNDS FOR USE AGAINST INFLAMMATION AND IMMUNE DISORDERS |
US8455658B2 (en) | 2006-01-25 | 2013-06-04 | Synta Pharmaceuticals Corp. | Thiazole and thiadiazole compounds for inflammation and immune-related uses |
US7816535B2 (en) | 2006-01-25 | 2010-10-19 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
AU2007211276B2 (en) | 2006-01-31 | 2013-06-06 | Synta Pharmaceuticals Corp. | Pyridylphenyl compounds for inflammation and immune-related uses |
US7951824B2 (en) | 2006-02-17 | 2011-05-31 | Hoffman-La Roche Inc. | 4-aryl-pyridine-2-carboxyamide derivatives |
US8119643B2 (en) | 2006-03-20 | 2012-02-21 | Synta Pharmaceuticals Corp. | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses |
AU2007230911A1 (en) | 2006-03-23 | 2007-10-04 | Synta Pharmaceuticals Corp. | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses |
WO2007120600A2 (en) | 2006-04-10 | 2007-10-25 | Arena Pharmaceuticals, Inc. | 3-pyridinyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
CA2659682C (en) | 2006-06-26 | 2010-12-21 | The Procter & Gamble Company | Prolyl hydroxylase inhibitors and methods of use |
US20080207641A1 (en) | 2006-11-13 | 2008-08-28 | Synta Pharmaceuticals Corp. | Cyclohexenyl-aryl compounds for inflammation and immune-related uses |
EP2129219A4 (en) | 2007-02-16 | 2012-08-29 | Synta Pharmaceuticals Corp | SUBSTITUTED FUSED CYCLE COMPOUNDS USED IN CASES OF INFLAMMATION OR IMMUNE DISORDERS |
DK2157979T3 (en) | 2007-05-24 | 2018-08-27 | Calcimedica Inc | CALCIUM CHANNEL PROTEINS AND APPLICATIONS THEREOF |
US8349841B2 (en) | 2007-08-01 | 2013-01-08 | Synta Pharmaceuticals Corp. | Vinyl-aryl derivatives for inflammation and immune-related uses |
CA2695143A1 (en) | 2007-08-01 | 2009-02-05 | Synta Pharmaceuticals Corp. | Heterocycle-aryl compounds for inflammation and immune-related uses |
AU2008284268A1 (en) | 2007-08-09 | 2009-02-12 | Merck & Co., Inc. | Pyridine carboxamide orexin receptor antagonists |
CA2699157A1 (en) | 2007-09-10 | 2009-03-19 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
JP2011509261A (ja) | 2008-01-07 | 2011-03-24 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連用途向けの化合物 |
FR2927330B1 (fr) | 2008-02-07 | 2010-02-19 | Sanofi Aventis | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii |
WO2009111280A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
JP2011515376A (ja) | 2008-03-20 | 2011-05-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 病的血栓形成に必須であるカルシウムセンサSTIM1及び血小板SOCチャネルOrai1(CRACM1) |
US20100016598A1 (en) | 2008-07-16 | 2010-01-21 | Wyeth | Alpha7 nicotinic acetylcholine receptor inhibitors |
MX2011002149A (es) | 2008-08-27 | 2011-04-05 | Calcimedica Inc | Compuestos que modulan el calcio intracelular. |
US8524763B2 (en) | 2008-09-22 | 2013-09-03 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
WO2010034011A2 (en) | 2008-09-22 | 2010-03-25 | Calcimedica, Inc. | Phenylthiophenyldihydrobenzothiazepine inhibitors of store operated calcium release |
CA2739303A1 (en) | 2008-10-01 | 2010-04-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
WO2010039237A1 (en) | 2008-10-01 | 2010-04-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
US20110230536A1 (en) | 2008-10-24 | 2011-09-22 | Calcimedica, Inc. | Phenylpyrazole inhibitors of store operated calcium release |
EP2421834A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
TW201103892A (en) | 2009-04-24 | 2011-02-01 | Glaxo Group Ltd | Compounds |
AU2010254180B2 (en) | 2009-05-27 | 2015-08-27 | Alkermes Pharma Ireland Limited | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
US8618307B2 (en) | 2009-09-16 | 2013-12-31 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
TW201129379A (en) | 2009-11-20 | 2011-09-01 | Amgen Inc | Anti-Orai1 antigen binding proteins and uses thereof |
US8476006B2 (en) * | 2009-11-30 | 2013-07-02 | National Center For Biological Sciences | Store-operated calcium cellular assay |
JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
WO2011139489A2 (en) | 2010-04-27 | 2011-11-10 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
AU2011248579A1 (en) | 2010-04-27 | 2012-11-29 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US9079891B2 (en) | 2010-08-27 | 2015-07-14 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US9604978B2 (en) | 2011-05-03 | 2017-03-28 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
US20130143927A1 (en) | 2011-06-10 | 2013-06-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
WO2012170931A2 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
WO2013059677A1 (en) | 2011-10-19 | 2013-04-25 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
AU2012325901A1 (en) * | 2011-10-19 | 2014-05-15 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
JP5936350B2 (ja) | 2011-12-27 | 2016-06-22 | キヤノン株式会社 | 新規有機化合物 |
WO2013164769A1 (en) * | 2012-05-02 | 2013-11-07 | Lupin Limited | Substituted pyridine compounds as crac modulators |
WO2014043715A1 (en) * | 2012-09-17 | 2014-03-20 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
EP3010586A1 (en) | 2013-06-21 | 2016-04-27 | Lupin Limited | Substituted heterocyclic compounds as crac modulators |
DK3778595T3 (da) | 2015-02-27 | 2021-10-18 | Calcimedica Inc | Pancreatitisbehandling |
EP3331525B1 (en) | 2015-08-07 | 2020-10-07 | Calcimedica, Inc. | Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury |
JP2020506179A (ja) | 2017-01-26 | 2020-02-27 | カルシメディカ,インク. | Cracチャネル阻害剤組成物 |
US20210338630A1 (en) | 2018-10-04 | 2021-11-04 | The Trustees Of Indiana University | Methods to treat renal disorders using calcium channel inhibitors |
CA3172249A1 (en) | 2020-03-20 | 2021-09-23 | Calcimedica, Inc. | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome |
EP4153179A1 (en) | 2020-05-20 | 2023-03-29 | Calcimedica, Inc. | Methods and compositions for treating acute kidney injury |
-
2016
- 2016-02-26 DK DK20200080.8T patent/DK3778595T3/da active
- 2016-02-26 AU AU2016224993A patent/AU2016224993B2/en active Active
- 2016-02-26 AR ARP160100518A patent/AR103807A1/es unknown
- 2016-02-26 ES ES20200080T patent/ES2899197T3/es active Active
- 2016-02-26 WO PCT/US2016/019924 patent/WO2016138472A1/en active Application Filing
- 2016-02-26 CN CN201680024735.5A patent/CN107530333B/zh active Active
- 2016-02-26 PT PT202000808T patent/PT3778595T/pt unknown
- 2016-02-26 HU HUE20200080A patent/HUE056287T2/hu unknown
- 2016-02-26 CN CN202210191615.1A patent/CN114712513A/zh active Pending
- 2016-02-26 ES ES16756509T patent/ES2959658T3/es active Active
- 2016-02-26 KR KR1020177026940A patent/KR20180006880A/ko not_active Application Discontinuation
- 2016-02-26 CA CA2978007A patent/CA2978007A1/en active Pending
- 2016-02-26 EA EA201791811A patent/EA036265B1/ru unknown
- 2016-02-26 BR BR112017018413-3A patent/BR112017018413B1/pt active IP Right Grant
- 2016-02-26 TW TW105106002A patent/TWI771269B/zh active
- 2016-02-26 JP JP2017544866A patent/JP6985146B2/ja active Active
- 2016-02-26 EP EP20200080.8A patent/EP3778595B1/en active Active
- 2016-02-26 EA EA202091639A patent/EA202091639A3/ru unknown
- 2016-02-26 EP EP23184730.2A patent/EP4275705A3/en active Pending
- 2016-02-26 PL PL20200080T patent/PL3778595T3/pl unknown
- 2016-02-26 US US15/553,531 patent/US11311535B2/en active Active
- 2016-02-26 EP EP16756509.2A patent/EP3261641B1/en active Active
- 2016-02-26 CN CN202010670349.1A patent/CN111773391A/zh active Pending
-
2017
- 2017-08-23 IL IL254116A patent/IL254116B2/en unknown
-
2018
- 2018-03-26 HK HK18104153.5A patent/HK1244686A1/zh unknown
-
2020
- 2020-08-07 US US16/988,508 patent/US10821109B1/en active Active
- 2020-10-22 US US17/077,818 patent/US11013737B2/en active Active
-
2021
- 2021-03-16 US US17/203,547 patent/US11752148B2/en active Active
- 2021-08-26 JP JP2021138203A patent/JP2021193097A/ja active Pending
- 2021-09-10 US US17/472,422 patent/US11439639B2/en active Active
-
2023
- 2023-06-02 JP JP2023091769A patent/JP2023116577A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FIC20230006I1 (fi) | Vutrisiraani | |
BR112017018413A2 (pt) | tratamento de pancreatite | |
DK3283625T3 (da) | Nukleasemedieret genomeditering | |
DK3331869T3 (da) | Muscarinagonister | |
DK3305788T3 (da) | Janus-kinase-hæmmer | |
DK3277719T3 (da) | Polypeptider | |
DK3331528T3 (da) | Muskarinagonister | |
DK3360890T3 (da) | Genterapi | |
DK3310450T3 (da) | Olie-vand-separator | |
DK3231444T3 (da) | Ny behandling | |
DK3331529T3 (da) | Muskarinagonister | |
DK3270930T3 (da) | Præeklampsi | |
BR112018000204A2 (pt) | métodos de tratamento de colite | |
DK3292136T3 (da) | Penicillin-g-acylaser | |
DK3394281T3 (da) | Gærcelle | |
DE112015006486A5 (de) | Inkubationsrinne | |
DK3318308T3 (da) | Badmintonketsjer | |
DK3274482T3 (da) | Stenborsknop | |
DE112016005599A5 (de) | Strahlungsgrill | |
DK3331600T3 (da) | Kateter | |
DE112015005898A5 (de) | Gurtschlossbringer | |
DE102015206660A8 (de) | Plattenaufteilanlage | |
DK3307184T3 (da) | Implantatfjerner | |
DE112016001124A5 (de) | Spannschutz | |
FI20155649A (fi) | Jaettu runko |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/02/2016, OBSERVADAS AS CONDICOES LEGAIS |